TPM3 and glioblastoma: Crizotinib and ponatinib are multitarget TRK inhibitors that have entered clinical trials in newly diagnosed GBM (nGBM) and recurrent GBM patients (NCT02270034 and NCT02478164), but the patients involved have unknown NTRK fusion status (9, 65).